List of GLP-1 receptor agonists: difference between revisions
Diff·revision 15 → 16·02:16, 11 May 2025
Difference between revision 15 and revision 16 of List of GLP-1 receptor agonists. 8 lines changed; the page grew by 387 bytes.
| Revision 15 — 04:47, 12 Apr 2025 PriorAuthPaz (talk) split the list at the point where the subject changes 3,023 bytes ±0 | Revision 16 — 02:16, 11 May 2025 OrphanPageOrin (talk) consistent en dashes in ranges 3,410 bytes +387 | ||
|---|---|---|---|
| 36 | These are treated at [[Dual incretin agonist]] and [[Triple agonist]]. Their receptor ratios are fixed by chemistry and are not comparable between publications, since reported potencies are assay-dependent.{{r|drucker2018}} | 36 | These are treated at [[Dual incretin agonist]] and [[Triple agonist]]. Their receptor ratios are fixed by chemistry and are not comparable between publications, since reported potencies are assay-dependent.{{r|drucker2018}} |
| 37 | 37 | ||
| + | 38 | == Related compounds == | |
| + | 39 | Not agonists at the GLP-1 receptor, but discussed alongside them: | |
| + | 40 | ||
| + | 41 | * [[Cagrilintide]] — an [[Amylin receptor agonist|amylin analogue]], combined with semaglutide as [[CagriSema]]. | |
| + | 42 | * Insulin icodec — a weekly basal insulin; a different mechanism entirely. | |
| + | 43 | * DPP-4 inhibitors — raise endogenous incretin rather than agonising the receptor. | |
| + | 44 | ||
| 38 | == References == | 45 | == References == |
| 39 | {{reflist}} | 46 | {{reflist}} |
| ⋮ | ⋮ | ||
| 47 | * [[Dual incretin agonist]] | 54 | * [[Dual incretin agonist]] |
| 48 | * [[Timeline of incretin therapeutics]] | 55 | * [[Timeline of incretin therapeutics]] |
| + | 56 | * [[Semaglutide]] | |
| 49 | 57 | ||
| 50 | {{DEFAULTSORT:List of GLP-1 receptor agonists}} | 58 | {{DEFAULTSORT:List of GLP-1 receptor agonists}} |